These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22584733)

  • 41. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
    Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
    Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Exploratory Randomized Trial of Physical Therapy for the Treatment of Chemotherapy-Induced Peripheral Neuropathy.
    Andersen Hammond E; Pitz M; Steinfeld K; Lambert P; Shay B
    Neurorehabil Neural Repair; 2020 Mar; 34(3):235-246. PubMed ID: 31976819
    [No Abstract]   [Full Text] [Related]  

  • 44. Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
    Shigematsu H; Hirata T; Nishina M; Yasui D; Ozaki S
    Support Care Cancer; 2020 Oct; 28(10):5005-5011. PubMed ID: 32036471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial.
    Kurt S; Can G
    Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
    Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
    Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
    J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.
    Accordino MK; Lee S; Leu CS; Levin B; Trivedi MS; Crew KD; Kalinsky K; Raghunathan R; Faheem K; Harden E; Taboada A; de Oliveira BD; Larson E; Franks L; Honan E; Law C; Hershman DL
    Breast Cancer Res Treat; 2024 Feb; 204(1):49-59. PubMed ID: 38060077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).
    Mongiovi JM; Zirpoli GR; Cannioto R; Sucheston-Campbell LE; Hershman DL; Unger JM; Moore HCF; Stewart JA; Isaacs C; Hobday TJ; Salim M; Hortobagyi GN; Gralow JR; Thomas Budd G; Albain KS; Ambrosone CB; McCann SE
    Breast Cancer Res; 2018 Nov; 20(1):146. PubMed ID: 30486865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similarities in the Neuropathy Phenotype of Cancer Survivors Who Received Different Classes of Chemotherapy Drugs.
    Miaskowski C; Levine JD; Paul SM; Cooper B; Abrams G; Topp K; Cheung S; Henderson-Sabes J; Conley YP; Snowberg K; Alfaro E; Quinn M; Kober KM
    J Pain; 2022 Sep; 23(9):1604-1615. PubMed ID: 35533976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Referred symptom from myofascial pain syndrome: One of the most important causes of sensory disturbance in breast cancer patients using taxanes.
    Ko EJ; Jeon JY; Kim W; Hong JY; Yi YG
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28004441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
    Han HS; Ro J; Lee KS; Nam BH; Seo JA; Lee DH; Lee H; Lee ES; Kang HS; Kim SW
    Breast Cancer Res Treat; 2009 May; 115(2):335-42. PubMed ID: 18506620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
    Greenlee H; Crew KD; Capodice J; Awad D; Buono D; Shi Z; Jeffres A; Wyse S; Whitman W; Trivedi MS; Kalinsky K; Hershman DL
    Breast Cancer Res Treat; 2016 Apr; 156(3):453-464. PubMed ID: 27013473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
    Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
    Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.